Kvika banki hf.: Transaction in relation to a share buyback programme
In week 36 Kvika banki hf. („Kvika“ or „the bank“) purchased 4,500,000 of its own shares at the purchase price 74,315,000 ISK. See further details below:
| Date | Time | No. of shares purchased | Share price (rate) | Purchase price |
| 4.9.2023 | 10:28:56 | 250,000 | 16.850 | 4,212,500 |
| 4.9.2023 | 11:49:55 | 250,000 | 16.850 | 4,212,500 |
| 4.9.2023 | 13:42:55 | 250,000 | 16.850 | 4,212,500 |
| 4.9.2023 | 15:08:18 | 250,000 | 16.800 | 4,200,000 |
| 5.9.2023 | 11:06:13 | 250,000 | 16.600 | 4,150,000 |
| 5.9.2023 | 13:47:42 | 500,000 | 16.650 | 8,325,000 |
| 5.9.2023 | 15:28:16 | 250,000 | 16.400 | 4,100,000 |
| 6.9.2023 | 14:14:55 | 200,000 | 16.400 | 3,280,000 |
| 6.9.2023 | 15:06:11 | 500,000 | 16.425 | 8,212,500 |
| 7.9.2023 | 11:11:24 | 300,000 | 16.325 | 4,897,500 |
| 7.9.2023 | 13:54:54 | 500,000 | 16.325 | 8,162,500 |
| 8.9.2023 | 11:24:15 | 500,000 | 16.350 | 8,175,000 |
| 8.9.2023 | 14:15:02 | 250,000 | 16.350 | 4,087,500 |
| 8.9.2023 | 15:13:15 | 250,000 | 16.350 | 4,087,500 |
| Total | 4,500,000 | 74,315,000 |
The trade is in accordance with Kvika‘s buyback programme, announced on 23 June 2023 and based on the authorisation of a shareholders‘ meeting of Kvika held on 30 March 2023.
Kvika held 45,950,000 own shares prior to the notified transacton and has, thus, purchased a total of 50,450,000 shares under the buyback programme, which corresponds to 1.055% of issued shares in the company. Total purchase price is 864,984,500 ISK. Buyback under the programme will amount to a maximum purchase price of 1,000,000,000 ISK.
The buyback programme is in effect from 23 June 2023 until Kvika‘s annual general meeting 2024, unless the maximum purchase price will be reached before that time.
The execution of the buy-back programme must comply with Act on Public Limited Companies, No. 2/1995. In addition, the buy-back programme must be implemented as provided for in the Regulation of the European Parliament and of the Council no. 596/2014, on market abuse, as well as the Commission Delegated Regulation (EU) 2016/1052 on regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures, which supplements that Regulation, cf. Act No. 60/2021 on Actions against Market Abuse.
Further information please contact Kvika‘s investor relations, ir@kvika.is
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ensurge Micropower ASA - Approval and publication of prospectus; commencement of subscription period in Subsequent Offering30.11.2023 19:32:57 CET | Press release
Reference is made to the stock exchange announcement published on 18 October 2023 by Ensurge Micropower ASA ("Ensurge" or the "Company"), regarding the successful placement of new shares, through an allocation of 122,846,875 new shares in Tranche 1 (the "Tranche 1 Shares") and an allocation of 352,153,125 new shares in Tranche 2 (the "Tranche 2 Shares"), as well as a possible subsequent repair offering raising up to NOK 12.5 million through the offering of up to 125,000,000 shares (the "Offer Shares") on similar terms as the private placement (the "Subsequent Offering"). As stated in the stock exchange announcement on 18 October 2023, the Subsequent Offering and the trading of the Tranche 2 Shares remained subject to approval of a prospectus by the Financial Supervisory Authority of Norway. Further reference is made to the Extraordinary General Meeting held on 10 November 2023 approving the issuance of the Tranche 2 Shares and the Subsequent Offering. The Financial Supervisory Authorit
Acronis Named a Leader in the IDC MarketScape: Worldwide Cyber-Recovery 2023 Vendor Assessment30.11.2023 18:59:51 CET | Press release
BURLINGTON, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Acronis, the global leader in cyber protection, today announced it had been identified as a Leader in the IDC MarketScape: Worldwide Cyber Recovery 2023 Vendor Assessment (doc #US49787923, November 2023). This is the first IDC MarketScape report about cyber recovery which illustrates the growing importance of both proactive defense and reactive recovery within an organization’s ability to deal with cyberattacks. The IDC MarketScape report cites Acronis’ key offerings, including a single agent that simplifies deployment and enables unique integration capabilities as well as integrated end-point protection. “Acronis was one of the first data protection vendors to identify and target the cyber recovery marketplace nearly five years ago and to rearchitect their solution specifically for cyber recovery,” the IDC MarketScape noted. Additionally, when referencing the company’s fundraising efforts in the past couple of years, the IDC MarketS
Tangem Sets New Standards for Crypto Hardware Wallet Integrity: Introducing Firmware Attestation, Audited by Riscure30.11.2023 18:54:27 CET | Press release
ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tangem AG, a leading crypto hardware wallet manufacturer, is thrilled to announce an in-depth software audit of the Tangem Wallet by Riscure, a renowned independent security lab specializing in evaluating the security of embedded software, chips, and devices. This constitutes Tangem's second consecutive security audit success, following a rigorous evaluation by Kudelski Security in 2018, which affirmed the absence of risks, malicious features and backdoors in the hardware wallet. The seamless outcomes of both audits underscore Tangem's unwavering commitment to maintaining the highest standards of security in its products. In this assessment, Riscure examined the source code and architecture of Tangem’s crypto wallet, testing all functionalities and commands accessible through the NFC interface. The primary goal was to identify potential vulnerabilities and logic-related security issues. The security evaluation did not reveal security
Dutch Court Orders Greenpeace Protesters Off NORI Research Vessel, Greenpeace Complies30.11.2023 18:42:09 CET | Press release
The District Court of Amsterdam has ordered Greenpeace International to immediately disembark from the research vessel commissioned by TMC subsidiary Nauru Ocean Resources Inc (NORI) to conduct legally-mandated environmental impact assessments requested by the Legal and Technical Commission of the International Seabed Authority (ISA) Since November 23rd, Greenpeace’s unsafe and unlawful activities have hindered independent scientists in conducting environmental and scientific studies to assess ecosystem function and recovery one year on from NORI’s pilot nodule collection system testNORI commends Greenpeace’s prompt effort to comply with the court order and looks forward to collaborating to ensure the safety of all personnel at sea NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TMC The Metals Company Inc. (“TMC” or “The Metals Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today announced that the District Court of Amsterdam in the Netherlands ha
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis30.11.2023 18:23:37 CET | Press release
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis Recruitment led by Grenoble Alpes University Hospital, driven by strong clinical sites participation and investigator support Topline data expected in Q4 2024 Paris (France), November, 30th 2023 – NH TherAguix a Phase 2 biotech company developing AGuIX®, an innovative nanodrug to improve cancer treatment by radiotherapy, announces the completion of recruitment in its NANORAD 2 Phase 2 clinical trial, randomized, multi-center study assessing safety and efficacy of AGuIX® in combination with whole brain radiation therapy versus whole brain radiation therapy alone, in adult patients with multiple brain metastasis. NANORAD 21 is a prospective randomized (1:1) open label trial with a total of 100 patients recruited in 14 active centers coordinated by Dr Camille Verry (CHUGA, Grenoble-Alpes, France) as principal investigator. This trial combines the rad